These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35372783)

  • 1. Monitoring the safety of influenza A/H1N1 pandemic and seasonal vaccines in Morocco.
    Tebaa A; Benkirane R; Alj L; Cherkaoui I; Soulaymani-Bencheikh R
    Ther Adv Vaccines Immunother; 2022; 10():25151355221088157. PubMed ID: 35372783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.
    van Puijenbroek EP; Broos N; van Grootheest K
    Drug Saf; 2010 Dec; 33(12):1097-108. PubMed ID: 21077700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea.
    Kim JH; Cho HY; Hennessey KA; Lee HJ; Bae GR; Kim HC
    Jpn J Infect Dis; 2012; 65(2):99-104. PubMed ID: 22446114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
    Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacovigilance study of influenza A H1N1 vaccination during the 2009-2010 season in France].
    Montastruc JL;
    Bull Acad Natl Med; 2011 Jun; 195(6):1309-16; discussion 1316-7. PubMed ID: 22530521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
    Clothier HJ; Crawford N; Russell MA; Buttery JP
    Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of seasonal trivalent influenza vaccine produced by Instituto Butantan from 2013 to 2017.
    Gattás VL; Braga PE; Koike ME; Lucchesi MBB; Oliveira MMM; Piorelli RO; Queiroz V; Precioso AR
    Rev Inst Med Trop Sao Paulo; 2018 Dec; 61():e4. PubMed ID: 30570077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.
    Ankrah DN; Mantel-Teeuwisse AK; De Bruin ML; Amoo PK; Ofei-Palm CN; Agyepong I; Leufkens HG
    Drug Saf; 2013 Apr; 36(4):259-66. PubMed ID: 23508545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
    Masuka JT; Khoza S
    BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual report: surveillance of adverse events following immunisation in Australia, 2009.
    Mahajan D; Roomiani I; Gold MS; Lawrence GL; McIntyre PB; Menzies RI
    Commun Dis Intell Q Rep; 2010 Sep; 34(3):259-76. PubMed ID: 21090181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.
    Bettinger JA; De Serres G; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; Top KA; Isenor JE; McCarthy AE;
    Euro Surveill; 2020 Jun; 25(22):. PubMed ID: 32524947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination].
    Ji WY; Lu L; Lü M; Miao L; Gao T; Huang RG; Suo LD; Liu DL; Ma R; Yu R; Zhangzhu JZ; Liu WX; Zeng Y; Li XM; Wu J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 May; 31(5):481-4. PubMed ID: 21163019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance.
    Kurz X; Domergue F; Slattery J; Segec A; Szmigiel A; Hidalgo-Simon A
    Vaccine; 2011 Jun; 29(26):4378-87. PubMed ID: 21501644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on surveillance data of adverse events following immunization of seasonal influenza vaccine in China during 2015-2018 influenza season].
    Wu WD; Li KL; Xu DS; Ye JK; Xiao QY; Wang HQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):987-992. PubMed ID: 31607043
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Seasonal and pandemic A (H1N1) 2009 influenza vaccination coverage among health-care workers in a French university hospital].
    Boyeau C; Tanguy M; Pean S; Delhumeau A; Fanello S
    Sante Publique; 2011; 23(1):19-29. PubMed ID: 21786736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.